Alpha Thalassaemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Alpha Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions.
Alpha thalassaemia (or α-thalassaemia) is a group of inherited blood disorders, characterised by a reduced production of the α-globin chains of the haemoglobin molecule, while the β-globin chains are normally produced. This means that there will be an accumulation of the β-(unpaired) globin chains, within the developing red cell. The production of the α-globin chains is regulated by four α-genes, two on each chromosome
The Alpha Thalassaemia drugs in development market research report provide comprehensive information on the therapeutics under development for Alpha Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alpha Thalassaemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Alpha Thalassaemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 7 molecules, with 7 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Alpha Thalassaemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Alpha Thalassaemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Alpha Thalassaemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Agios Pharmaceuticals IncGenmedicn Biopharma Ltd
Guangzhou Reforgene Medicine Co Ltd
Merck & Co Inc
Shanghai Pharmaceuticals Holding Co Ltd
Shenzhen Hemogen Gene Biotechnology Co Ltd
Silence Therapeutics Plc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Alpha Thalassaemia reports